ClinicalTrials.gg
RecruitingNCT06907446Updated Aug 6, 2026

Comparison of New SUREcore Biopsy of Needle to Standard of Care During Transperineal Prostate Biopsies

An interventional study of Comparison of Biopsy Needle Types for Prostate Biopsy in Prostate Cancer, sponsored by University of California, Davis. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by University of California, Davis · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Prostatic Neoplasms by University of California, Davis — 5 open to participants now, 5 under way, none of them phase 3. Prostatic Neoplasms · University of California, Davis.

Planned enrollment
6th of 15
50 · median 30
Started
2025
the only one that year
No phase
6 of 19
3 open now
Registered
19th of 19
by date

Among the 19 studies in Prostatic Neoplasms by University of California, Davis, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 6 with no phase, and was the 19th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 19 studies in Prostatic Neoplasms by University of California, Davis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Prostatic Neoplasms by University of California, Davis, or all of them as a file.
02

Study summary

To study a novel biopsy needle system for performing transperineal prostate biopsy. Prostate biopsy remains the standard approach for prostate cancer detection. While pre-biopsy MRI allows for targeting of visible lesions, systemic or 'off target' samples are recommended due to the well-recognized risk of undegrading and under sampling with current commercially available needles. The SureCore plus single-use biopsy needle produces a more intact tissue core with a same caliber 18g needle with \~21% more tissue per core in pre-clinical studies. This research study will determine if a new biopsy needle designed to produce more robust tissue cores per sample can improve detection and characterization of prostate cancer.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient older than age of 18 undergoing prostate

Exclusion criteria

Exclusion Criteria:

  • Unable to consent
  • Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives
  • Prisoners
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Other
    Single arm study comparing two different needle biopsy systems for prostate biopsy

    Diagnostic Test: Comparison of Biopsy Needle Types for Prostate Biopsy

Interventions

  • Diagnostic testComparison of Biopsy Needle Types for Prostate Biopsy

    Each patient will undergo a standard of care prostate biopsy according to the clinical indication alternating between the SureCore and standard Bard needle

06

What researchers measure

Primary outcomes

  1. Number of patients diagnosed with prostate cancer and histological grade of cancer detected

    The primary outcome will evaluate whether cancer is detected on final pathological analysis. This will include the grade of cancer, percentage of core involved, and compare between the two needles.

    Time frame: From prostate biopsy procedure through study completion up to 1 year

Secondary outcomes

  1. Quality of Biopsy Specimen Obtained at Time of Prostate Biopsy

    The secondary outcomes will look at the quality of specimen including fragmentation, tortuosity, and spatial orientation of the sample.

    Time frame: From prostate biopsy procedure through study completion up to 1 year

  2. Length of time necessary to diagnose the tissue sample

    Time required from collection of specimen to final diagnosis.

    Time frame: Diagnosis within 10 days of the biopsy

07

Study locations

1 of 1 sites recruiting
  • UC Davis Departments of Urologic Oncology
    Sacramento, California 95817, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jul 2027, 26 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 26 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Apr 2, 2025
StartActual
May 1, 2025
Primary completionEst.
Jul 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06907446
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
May 1, 2025
Primary completion
Jul 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Aug 6, 2026

Study contacts

Marc Dall'Era, MD
Contact
mdallera@ucdavis.edu
916-734-2893
Elisa Lee
Contact
elilee@ucdavis.edu
916-734-5173

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion